Cassava Sciences reports Q2 net income, $40M SEC loss contingency, Phase 3 readout timeline

FILANA THERAPEUTICS, INC.

2024-Q2 EPS reported -$0.28

Q2 net income $6.2M vs net loss $26.4M in 2023, driven by non-cash warrant gain.
Recorded $40M loss contingency for advanced discussions to resolve SEC investigation.
Cash $207.3M at June 30, 2024; no debt; warrants fully exercised.
Phase 3 RETHINK-ALZ top-line data expected by end of 2024; REFOCUS-ALZ mid-2025.
Audit Committee vacancy due to director death; Nasdaq noncompliance; cure until Aug 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.